Takeda Pharmaceutical Company Limited and TG Therapeutics, Inc.: A Comprehensive Revenue Analysis

Takeda vs. TG Therapeutics: A Decade of Revenue Dynamics

__timestampTG Therapeutics, Inc.Takeda Pharmaceutical Company Limited
Wednesday, January 1, 20141523811777824000000
Thursday, January 1, 20151523811807378000000
Friday, January 1, 20161523811732051000000
Sunday, January 1, 20171523811770531000000
Monday, January 1, 20181520002097224000000
Tuesday, January 1, 20191520003291188000000
Wednesday, January 1, 20201520003197812000000
Friday, January 1, 202166890003569006000000
Saturday, January 1, 202227850004027478000000
Sunday, January 1, 20232336620004263762000000
Monday, January 1, 20244263762000000
Loading chart...

Unlocking the unknown

A Tale of Two Companies: Revenue Trends from 2014 to 2023

In the dynamic world of pharmaceuticals, Takeda Pharmaceutical Company Limited and TG Therapeutics, Inc. present a fascinating study in contrasts. Over the past decade, Takeda has demonstrated a robust growth trajectory, with revenues soaring from approximately $1.78 trillion in 2014 to an impressive $4.26 trillion by 2023. This represents a staggering 140% increase, underscoring Takeda's dominance in the global pharmaceutical landscape.

Conversely, TG Therapeutics, Inc. has experienced a more volatile journey. Starting with modest revenues of around $152,000 in 2014, the company saw a significant spike in 2023, reaching $233 million. This dramatic increase highlights TG Therapeutics' potential for growth, albeit from a smaller base.

While Takeda's consistent growth reflects its established market presence, TG Therapeutics' recent surge suggests a promising future, albeit with some data gaps in 2024 that warrant further observation.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025